Skip to content
Companies

Cyrus Biotechnology

Computational protein design for drug discovery

Raised to date

$1.5M

of $3M offered across 1 Form D filing

Still open
$1.5M
Investors
17
Last filed
May 8, 2026

About

Cyrus Biotechnology is a computationally-driven protein design company spun out of the University of Washington's Institute for Protein Design in 2014. It combines computational modeling and deep mutagenesis to engineer naturally occurring proteins into therapeutics, and originally commercialized the work as Cyrus Bench, an enterprise version of the Rosetta molecular modeling and design toolkit. Since 2021 the company has also advanced its own preclinical pipeline, including an IdeS program for IgG-driven autoimmune disease, an IL-22 variant fusion protein, and ACE2v2-Fc for acute respiratory distress syndrome. Cyrus has run computational discovery and novel-IP work for more than 30 partner firms including Janssen, Genentech, Nimbus, and Selecta.

Direct lineage to the Rosetta protein design software from David Baker's lab, packaged as a commercial platform and then turned inward on the company's own therapeutic pipeline rather than sold only as tooling.

Funding

  • Security to be acquiredFiled May 8, 2026Form D/A
    $1.5M/ $3M

Product

Cyrus protein design platform

Computational drug discovery platform

A computational protein engineering platform that pairs novel algorithms with laboratory deep mutagenesis to redesign naturally occurring proteins into drug candidates, built on the Rosetta molecular modeling toolkit and commercialized to biopharma as Cyrus Bench.

  • Rosetta-based molecular modeling and protein design toolkit
  • DNA/RNA support integrated into the design platform
  • Deep mutagenesis paired with computational modeling

Built for

Pharmaceutical and biotech R&D organizations seeking engineered protein therapeutics, alongside patients with severe IgG-driven autoimmune and respiratory disease as the eventual beneficiaries of the internal pipeline

People on file